These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 7185544)

  • 1. Criteria for journal reports of suspected drug reactions.
    Jones JK
    Clin Pharm; 1982; 1(6):554-5. PubMed ID: 7185544
    [No Abstract]   [Full Text] [Related]  

  • 2. Submitting reports of adverse drug reactions to AJHP.
    Thompson CA
    Am J Hosp Pharm; 1994 Oct; 51(19):2358. PubMed ID: 7847399
    [No Abstract]   [Full Text] [Related]  

  • 3. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse drug reactions: reaching the F.D.A.
    Duffy P
    Nursing; 1989 Mar; 19(3):82. PubMed ID: 2927770
    [No Abstract]   [Full Text] [Related]  

  • 5. New short form for reporting adverse drug reactions.
    FDA Drug Bull; 1986 Jun; 16(1):4. PubMed ID: 3732679
    [No Abstract]   [Full Text] [Related]  

  • 6. Reporting of adverse drug reactions.
    Soletsky LM
    Postgrad Med; 1997 Jul; 102(1):35-6. PubMed ID: 9254389
    [No Abstract]   [Full Text] [Related]  

  • 7. [Minimal information that should be found in reports about suspected adverse reactions of drugs].
    Laporte JR; Lience E
    Med Clin (Barc); 1991 Jun; 97(2):56-7. PubMed ID: 1895784
    [No Abstract]   [Full Text] [Related]  

  • 8. Scientific paper or political 'white paper'?
    Fisher DW
    Hosp Pract (Off Ed); 1992 Jul; 27(7):13, 16. PubMed ID: 1629259
    [No Abstract]   [Full Text] [Related]  

  • 9. Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers.
    Bennett CL; Nebeker JR; Yarnold PR; Tigue CC; Dorr DA; McKoy JM; Edwards BJ; Hurdle JF; West DP; Lau DT; Angelotta C; Weitzman SA; Belknap SM; Djulbegovic B; Tallman MS; Kuzel TM; Benson AB; Evens A; Trifilio SM; Courtney DM; Raisch DW
    Arch Intern Med; 2007 May; 167(10):1041-9. PubMed ID: 17533207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advice to authors and reviewers of case reports on adverse drug reactions.
    Zellmer WA
    Clin Pharm; 1982; 1(6):555. PubMed ID: 7185545
    [No Abstract]   [Full Text] [Related]  

  • 11. Toward improved adverse event/suspected adverse drug reaction reporting.
    Gross R; Strom BL
    Pharmacoepidemiol Drug Saf; 2003 Mar; 12(2):89-91. PubMed ID: 12642971
    [No Abstract]   [Full Text] [Related]  

  • 12. The importance of the state medical journal to the pharmaceutical industry.
    Stetler CJ
    J Med Assoc Ga; 1968 Feb; 57(2):73-7. PubMed ID: 5639734
    [No Abstract]   [Full Text] [Related]  

  • 13. Institute of Medicine's new drug safety report: implications for Canada.
    Cassels A
    CMAJ; 2006 Dec; 175(12):1515-6. PubMed ID: 17146086
    [No Abstract]   [Full Text] [Related]  

  • 14. [How good are publications on undesirable drug effects?].
    Venulet J; Blattner R; von Bülow J; Berneker GC
    Wien Med Wochenschr; 1983 Nov; 133(22):573-6. PubMed ID: 6666159
    [No Abstract]   [Full Text] [Related]  

  • 15. Post-marketing drug surveillance: an idea whose time has come.
    Strom BL
    Drug Ther; 1982; ():155-63. PubMed ID: 7105991
    [No Abstract]   [Full Text] [Related]  

  • 16. Change in FDA definition of serious adverse drug event.
    Bader RL
    Am J Hosp Pharm; 1989 Jun; 46(6):1132. PubMed ID: 2750762
    [No Abstract]   [Full Text] [Related]  

  • 17. [Adverse drug reactions in the Spanish medical bibliographic literature: a comparison of 3 periods].
    López-Oliva AG; Vargas Castrillón E; García Mateos M; García Arenillas M; Terleira Fernández A; Moreno González A
    Med Clin (Barc); 1999 Jan; 112(2):55-6. PubMed ID: 10065430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse drug reactions, MedWatch reporting and medical student education.
    Lewis LD; Nierenberg DW
    Pharmacoepidemiol Drug Saf; 2003 Mar; 12(2):93-5. PubMed ID: 12642972
    [No Abstract]   [Full Text] [Related]  

  • 19. Assessments of pharmaceutical advertisements: a critical analysis of the criticism.
    Beales JH; MacLeod WC
    Food Drug Law J; 1995; 50(3):415-49. PubMed ID: 10343010
    [No Abstract]   [Full Text] [Related]  

  • 20. U.S. study of drug effectiveness could bring new drug recalls.
    Bowles GC
    Mod Hosp; 1966 Aug; 107(2):128. PubMed ID: 5952736
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.